Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19007278 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | December 2024 | April 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 18452514 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | August 2023 | November 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18192191 | INDUCIBLE CRISPR SYSTEM EXPRESSION AND APPLICATIONS THEREOF | March 2023 | December 2024 | Allow | 20 | 3 | 0 | Yes | No |
| 18170035 | COMPOSITION FOR PRIME EDITING COMPRISING PEGRNA FOR EDITING MUTATION OF ALPHA-1 ANTITRYPSIN DEFICIENCY | February 2023 | October 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17598274 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17436165 | METHODS OF TREATING AND DIAGNOSING EPILEPSY | September 2021 | December 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17430301 | DUAL INHIBITION OF PLEXIN-B1 AND PLEXIN-B2 | August 2021 | April 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17426416 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES OR CONDITIONS | July 2021 | April 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17426385 | CALCINEURIN INHIBITOR RESISTANT IMMUNE CELLS FOR USE IN ADOPTIVE CELL TRANSFER THERAPY | July 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17425485 | NR2E3 EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE | July 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17424476 | APTAMER AND USE OF THE APTAMER IN THE DIAGNOSIS AND TREATMENT OF CANCER | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17377590 | GENOMIC EDITING VECTOR FOR EUBACTERIUM CALLANDERI, METHOD FOR EDITING GENOME OF EUBACTERIUM CALLANDERI USING THE SAME, AND TRANSGENIC EUBACTERIUM CALLANDERI STRAINS USING THE SAME | July 2021 | January 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17423412 | COMPOSITION, METHOD AND USE THEREOF | July 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17413214 | CIS CONJUGATIVE PLASMID SYSTEM | June 2021 | May 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17338525 | METHOD OF PRODUCING A SIALYLATED N-GLYCOSYLATED RECOMBINANT PROTEIN IN PERIPLASM OF A RECOMBINANT ESCHERICHIA COLI | June 2021 | January 2025 | Allow | 44 | 2 | 0 | No | No |
| 17294859 | COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION | May 2021 | November 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17245531 | PHARMACOLOGIC TREATMENT FOR RIGHT VENTRICULAR FAILURE | April 2021 | June 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17283112 | Cells and Methods for the Production of Ursodeoxycholic Acid and Precursors Thereof | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17208831 | REVERSIBLY BLOCKED NUCLEOSIDE ANALOGUES AND THEIR USE | March 2021 | November 2024 | Allow | 43 | 2 | 1 | No | No |
| 17271432 | FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES | February 2021 | January 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17266270 | VARIANT TYPE V CRISPR/CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | February 2021 | January 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17264889 | METHOD FOR CONSTRUCTING THE RECOMBINANT YEASTS FOR PREPARATION OF TYROSOL AND DERIVATIVES AND ITS APPLICATION | February 2021 | April 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17251645 | METHODS OF EVALUATING TREATMENT OUTCOME IN HIGH GRADE SEROUS OVARIAN CANCER | December 2020 | May 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17055800 | INHIBITION OF FOLLISTATIN | November 2020 | February 2025 | Abandon | 51 | 1 | 1 | No | No |
| 16341563 | Epigenetically Regulated Site-Specific Nucleases | April 2019 | June 2025 | Abandon | 60 | 5 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner PERSONS, JENNA L works in Art Unit 1637 and has examined 24 patent applications in our dataset. With an allowance rate of 41.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner PERSONS, JENNA L's allowance rate of 41.7% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PERSONS, JENNA L receive 1.42 office actions before reaching final disposition. This places the examiner in the 31% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by PERSONS, JENNA L is 44 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +87.5% benefit to allowance rate for applications examined by PERSONS, JENNA L. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.0% of applications are subsequently allowed. This success rate is in the 50% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.